JARC – Joint Action on Rare Cancer
The Joint Action on Rare Cancers is a multistakeholders collaboration between 18 Member States and European Commission, coordinated by the Fondazione IRCCS Istituto Nazionale dei Tumori of Milan. There are 34 partners involved in the JARC including Ministries of Health/Cancer Control Programs representatives (Cyprus, Czech Republic, France, Ireland, Italy, Malta, Poland and Spain), universities, public health health institutions, population-based cancer registries, oncological onstitutes, patients associations (ECPC, EURORDIS, CCI-Europe) and other societies/organisations (including the Organization of European Cancer Institutes – OECI and European Society for Pediatric Oncology – SIOPE). This EU Joint Action on Rare Cancers should be viewed as a natural framework for all stakeholders to work together to: prioritize rare cancer, in the agenda of the EU and Member States, with a view to national cancer plans and quality of healthcare, harmonization of clinical practice, innovation through promotion of clinical and translational research; develop innovative and shared solutions, mainly to be implemented through the future ERNs on rare cancers, in the areas of quality of care, research, education and state of the art definition on prevention, diagnosis and treatment of rare cancers.
- Researcher:Maria Jose Sanchez Perez
- Group: A17-CANCER EPIDEMIOLOGY
- Centre: EASP – Andalusian School of Public Health
- Role in the project: Work Package Leader
- Duration: 2017-2019
Project website: https://jointactionrarecancers.eu/